ARC
REGN icon

Absolute Return Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Absolute Return Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,381
Closed -$5.76M – 875
2014
Q2 		$5.76M Buy
20,381
+15,373
+307% +$4.56M 0.07% 343
2014
Q1 		$1.5M Buy
+5,008
New +$1.54M 0.02% 565

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Absolute Return Capital's REGN Position: Q3 2014 in Review

Absolute Return Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2014, closing a stake of 20,381 shares — an estimated $5.76M sold.

Absolute Return Capital first reported a position in REGN in Q1 2014 and held it in 2 quarters. The position peaked at $5.76M in Q2 2014. 473 funds tracked by Wall St. Rank hold REGN as of Q3 2014.

  • Absolute Return Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 20,381 Regeneron Pharmaceuticals shares in Q3 2014, an estimated $5.76M.
  • Absolute Return Capital first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Absolute Return Capital's Regeneron Pharmaceuticals position peaked at $5.76M in Q2 2014.
  • 473 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.